An Open-label Phase 1 Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable Advanced and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation

Go Back to All Clinical Trials

An Open-label Phase 1 Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable Advanced and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Advanced Metastatic Solid Tumors
Age: Between 18 Year(s) - 99 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Any solid tumor histology positive for KRAS G12D
2. HLA*C:08:02

You may not be eligible for this study if the following are true:

1. History of other malignancies
2. History of stroke or transient ischemic attack within the previous 12 months
3. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, cardiac arrythmia requiring antiarrhythmic or procedure, or other clinically significant cardiac disease within the previous 6 months or heart failure at any time

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies